Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Escalating Study of ARO-C3 in Healthy Volunteers and Patients With Complement-Mediated Renal Disease
2023-506690-36-00Phase 2Completed
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- May 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 7
01
Overview
Phase 2 trial of ARO-C3 in complement mediated glomerular disease, Complement 3 glomerulopathy (C3G) and IgA nephropathy (IgAN) (2 arms), sponsored by Arrowhead Pharmaceuticals. Primary endpoint: Incidence, frequency, and severity of treatment-emergent adverse events (TEAEs). Started May 2024; status: completed.
02
Drugs
ARO-C3
03
Conditions
complement mediated glomerular diseaseComplement 3 glomerulopathy (C3G)IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2023-506690-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506690-36-00.